Table 1.

Outcomes of patients with hematologic malignancies and COVID-19

Study	MyeloidM								Lymphoid
	AML, %		MDS, %		MPN		unspecified myeloid		ALL, %		HL,%		NHL, %		plasma cell dyscrasia, %		unspecified lymphoid, %
Passamonti et al. [6]	43	51	49	41	33	83			19	16	18	17	38	222	37	106
García-Suárez et al. [7]	44	61	42	78	22	65			15	13	27	33	33	296	34	137
Pagano et al. [16, 93]	40	497	42	279	26	334			26	169	11	135	31	1,558	49	458
Grivas et al. [12]							18%	220							16	232	17%	641

Percentages reflect the mortality rates. Numbers in italics represent the samples sizes. AML, acute myeloid leukemia; MDS, myeloid dysplastic syndrome; MPN, myeloproliferative neoplasms, including Ph+ and Ph–; ALL, acute lymphocytic leukemia; HL, Hodgkin's lymphoma; NHL, non-Hodgkin's lymphoma.